Insider Transactions in Q1 2022 at Laboratory Corp Of America Holdings (LH)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 04
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
165
-1.68%
|
$45,705
$277.48 P/Share
|
|
Feb 04
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
560
+5.4%
|
-
|
|
Feb 04
2022
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
286
-0.65%
|
$79,222
$277.48 P/Share
|
|
Feb 04
2022
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
970
+2.16%
|
-
|
|
Feb 04
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
165
-1.64%
|
$45,705
$277.48 P/Share
|
|
Feb 04
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
560
+5.27%
|
-
|
|
Feb 04
2022
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
109
-0.74%
|
$30,193
$277.48 P/Share
|
|
Feb 04
2022
|
Lance Berberian EVP, CIO & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
373
+2.47%
|
-
|
|
Feb 03
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
172
-3.15%
|
$46,612
$271.81 P/Share
|
|
Feb 03
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
161
-2.45%
|
$43,631
$271.81 P/Share
|
|
Feb 02
2022
|
Jean Luc Belingard Director |
SELL
Payment of exercise price or tax liability
|
Direct |
78
-0.48%
|
$21,294
$273.18 P/Share
|
|
Feb 02
2022
|
Jean Luc Belingard Director |
BUY
Exercise of conversion of derivative security
|
Direct |
771
+4.51%
|
-
|
|
Feb 02
2022
|
Jeffrey A. Davis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
771
+28.55%
|
-
|
|
Feb 02
2022
|
Dwight Gary Gilliland Director |
BUY
Exercise of conversion of derivative security
|
Direct |
771
+9.89%
|
-
|
|
Feb 02
2022
|
Garheng Kong Director |
BUY
Exercise of conversion of derivative security
|
Direct |
771
+7.02%
|
-
|
|
Feb 02
2022
|
Richelle P Parham Director |
BUY
Exercise of conversion of derivative security
|
Direct |
771
+10.12%
|
-
|
|
Feb 02
2022
|
R Sanders Williams Director |
BUY
Exercise of conversion of derivative security
|
Direct |
771
+9.92%
|
-
|
|
Feb 02
2022
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
103
-0.71%
|
$28,119
$273.18 P/Share
|
|
Feb 02
2022
|
Lance Berberian EVP, CIO & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
296
+2.0%
|
-
|
|
Feb 02
2022
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
236
-0.55%
|
$64,428
$273.18 P/Share
|
|
Feb 02
2022
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
766
+1.74%
|
-
|
|
Feb 02
2022
|
Adam H Schechter President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
803
-5.29%
|
$219,219
$273.18 P/Share
|
|
Feb 02
2022
|
Adam H Schechter President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,773
+15.44%
|
-
|
|
Feb 02
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
147
-1.52%
|
$40,131
$273.18 P/Share
|
|
Feb 02
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
443
+4.38%
|
-
|
|
Feb 02
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
41
-3.64%
|
$11,193
$273.18 P/Share
|
|
Feb 02
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
116
+9.33%
|
-
|
|
Feb 02
2022
|
Judith C Seltz EVP, CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
76
-6.04%
|
$20,748
$273.18 P/Share
|
|
Feb 02
2022
|
Judith C Seltz EVP, CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
220
+14.89%
|
-
|
|
Feb 02
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
144
-1.53%
|
$39,312
$273.18 P/Share
|
|
Feb 02
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
443
+4.5%
|
-
|
|
Feb 02
2022
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
77
-19.64%
|
$21,021
$273.18 P/Share
|
|
Feb 02
2022
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
220
+35.95%
|
-
|
|
Feb 02
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
64
-1.16%
|
$17,472
$273.18 P/Share
|
|
Feb 02
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
236
+4.1%
|
-
|
|
Feb 02
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
121
-1.81%
|
$33,033
$273.18 P/Share
|
|
Feb 02
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
443
+6.22%
|
-
|
|
Feb 02
2022
|
Kerrii B Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
771
+3.8%
|
-
|
|
Feb 02
2022
|
Peter M Neupert Director |
BUY
Exercise of conversion of derivative security
|
Direct |
771
+10.25%
|
-
|